Molecular data
| Molecular formula | Mixture (GHK-Cu + TB-500 + BPC-157 + KPV) |
|---|---|
| Sequence | Components: GHK-Cu (Gly-His-Lys + Cu2+); TB-500 (Ac-LKKTETQ); BPC-157 (GEPPPGKPADDAGLV); KPV (Lys-Pro-Val) |
| Physical form | Lyophilized powder |
| Available sizes | 80mg |
How it works
Tissue Repair & Angiogenesis
In preclinical research, BPC-157 promotes skin, tendon, muscle and bone healing through growth-factor upregulation and angiogenic signaling. TB-500 (a thymosin β-4 fragment) is studied for promoting cell migration, reducing fibrosis, and enhancing regeneration across multiple injury models.
- BPC-157: growth-factor upregulation and angiogenesis in repair models
- TB-500: actin-binding effects on cell migration and regeneration
- Both studied across tendon, muscle, cardiac and dermal injury models
Matrix & Collagen Support
GHK-Cu is a copper-binding tripeptide studied for enhancing collagen and elastin synthesis, supporting angiogenesis, and stimulating fibroblast migration — making it a frequent reference compound in extracellular-matrix and skin-repair research.
- Enhances collagen and elastin synthesis in fibroblast models
- Supports angiogenesis and fibroblast migration
- Studied for extracellular-matrix remodeling and skin repair
Inflammation Modulation
KPV, the C-terminal tripeptide of α-MSH, inhibits NF-κB and MAP-kinase inflammatory signaling at nanomolar concentrations, reducing pro-inflammatory cytokine output — adding an anti-inflammatory axis to the blend's repair-focused components.
- Inhibits NF-κB and MAP-kinase inflammatory signaling
- Reduces TNF-α, IL-6 and IL-1β in research models
- Adds an anti-inflammatory dimension to the repair blend
What the research shows
Tendon, Muscle & Connective Tissue
BPC-157 and related repair peptides are studied in preclinical tendon, muscle and bone-healing models, with human validation still limited.
Sikiric et al. 1998
Cell Migration & Angiogenesis
BPC-157, TB-500 and GHK-Cu are frequently used together in in-vitro and ex-vivo systems to probe endothelial activity and matrix gene expression.
Ortho Sports Med. Review
Skin, Collagen & Wound Models
GHK-Cu is a reference compound for collagen/elastin synthesis and fibroblast research; the blend is studied in dermal-repair contexts.
Therapeutic Peptides Review
Recovery & Repair Pharmacology
Reviews of injectable peptide therapy examine the repair-focused peptide class, its mechanisms, and the current limits of the human evidence base.
Injectable Peptide Therapy Primer
Specification
| Product Type | Four-peptide research blend |
|---|---|
| Component 1 | GHK-Cu 50 mg — copper-binding tripeptide |
| Component 2 | TB-500 10 mg — thymosin β-4 fragment |
| Component 3 | BPC-157 10 mg — gastric pentadecapeptide |
| Component 4 | KPV 10 mg — α-MSH C-terminal tripeptide |
| Total Peptide Content | 80 mg per vial |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 14 days |
| COA | Included with every order |
Frequently asked questions
What is the KLOW blend?
KLOW is a four-peptide research blend combining GHK-Cu (50 mg), TB-500 (10 mg), BPC-157 (10 mg) and KPV (10 mg) — 80 mg of total peptide per vial. It groups together short peptides that are individually studied in tissue-repair, regeneration and anti-inflammatory research.
What does each peptide in KLOW do?
BPC-157 is studied for tendon, muscle and bone healing via growth-factor signaling; TB-500 (a thymosin β-4 fragment) for cell migration and reduced fibrosis; GHK-Cu for collagen synthesis and fibroblast activity; and KPV for NF-κB-mediated anti-inflammatory effects. Together they span repair, angiogenesis, matrix support and inflammation.
Why combine these four peptides?
Each component acts through different mechanisms relevant to tissue repair. Combining them creates a single research model that touches multiple pathways at once — angiogenesis and growth-factor signaling (BPC-157, TB-500), extracellular-matrix support (GHK-Cu), and inflammation modulation (KPV).
Is KLOW FDA approved?
No. None of the four components is an FDA-approved drug for tissue-repair indications. BPC-157 specifically is not approved by the FDA or EMA, and a 2023 FDA Category 2 designation restricts injectable compounding in the United States. Research-grade KLOW is supplied strictly for in vitro laboratory research.
What research contexts use these peptides?
BPC-157, TB-500 and GHK-Cu are used in in-vitro systems, ex-vivo tissue explants and animal models to study endpoints such as endothelial-cell activity in angiogenesis assays, fibroblast-associated matrix gene expression, cell migration and wound closure. KPV is used in inflammatory-signaling research.
How should the KLOW blend be stored?
Lyophilized KLOW should be stored at -20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, it should be kept at 2–8°C and used within approximately 14 days to preserve the integrity of all four peptides.
Literature
- PUBMED BPC 157's Effect on Healing
- PMC Emerging Use of BPC-157 in Orthopaedic Sports Medicine
- PMC Therapeutic Peptides in Orthopaedics
- PUBMED Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.